AIM movers: Kibo Mining restructuring and Safestay buys Brighton property

Angola-focused oil and gas company Corcel (LON: CRCL) has gained approvals to collect data for KON 11, KON 12 and KON 16 blocks in Angola. The survey will be done in the third quarter. There will be a financial update on 14 June. The share price rose 23.8% to 0.13p.

Norway-based First Seagull AS has acquired a 7.88% stake in Aferian (LON: AFRN). The share price is one-quarter higher at 4.5p.

- Advertisement -

Mathematical drug modelling company Physiomics (LON: PYC) has been awarded a contract by a UK biotech company. This will use the company’s virtual tumour technology. The project is valued at £162,000 and should be completed over five months. This will provide information for the reactivation of former oil and gas fields. The share price increased 7.69% to 1.4p.

Hostels operator Safestay (LON: SSTY) has acquired a property in Brighton from the University of East Sussex for £2.275m. This will be converted into a 220 bed premium hostel. It is 600 metres from the sea front and will cost £1m to convert. Shore Capital has been appointed nominated adviser and broker. Safestay reported full year revenues 18% higher at £22.5m. EBITDA rose 15% to £6.8m. NAV was 50p/share. The share price is 7.5% ahead at 21.5p.


Mohammmed Ashraf has been appointed chief executive of Kibo Energy (LON: KIBO) and James Parsons is joining the board to oversee a restructuring. The company will become a broader based energy company that includes oil and gas. There will be a review of existing interests. Stefania Barbaglio and Clive Roberts are also joining the board. The renewable energy company has raised £500,000 at 0.015p/share. The main assets are 83.2 million shares in MAST Energy Development (LON: MED) plus £849,000 owed by that company, 134.4 million shares in Katoro Gold (LON: KAT) and a portfolio of waste to energy projects. The receivable from MAST Energy Developments will be used to reduce the debt owed to RiverFort Global Opportunities from £767,000 to £400,000, which be structured as a two-year loan with a 10% annual interest rate. The Johannesburg Stock Exchange listing may be dropped. The share price slumped 46.7% to 0.016p.

- Advertisement -

Antimicrobial treatment developer Ondine Biomedical (LON: OBI) doubled 2023 revenues to $1.2m. Funding for the US phase 3 clinical trial for Steriwave is being explored and up to $22m is required to generate the data required. Ondine Biomedical raised $6.1m at 7p/share earlier this year. There are hospitals already using Steriwave to reduce the number of infections. The share price is 12.1% lower at 7.25p.

WIIT has decided not to make an offer for Redcentric (LON: RCN). The share price fell back 3.26% to 141p.

Latest News

Subscribe to the UK Investor Magazine email newsletter

Register for our free email newsletter and receive the latest investment news, podcasts, event information and offers.

More Articles Like This

Tagdiv Cloud library - template content.